98 filings
8-K
SHPH
Shuttle Pharmaceuticals Holdings Inc
14 May 24
Shuttle Pharma Provides First Quarter 2024 Corporate Update
9:00am
8-K
SHPH
Shuttle Pharmaceuticals Holdings Inc
29 Apr 24
Other Events
10:05am
8-K
SHPH
Shuttle Pharmaceuticals Holdings Inc
23 Apr 24
Other Events
4:36pm
S-1
SHPH
Shuttle Pharmaceuticals Holdings Inc
IPO registration
5 Apr 24
5:06pm
8-K
2wgym uenmu
22 Mar 24
Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update
9:00am
424B3
3dk2kwv jat6
22 Mar 24
Prospectus supplement
6:07am
8-K
atw a4l70rz6ry05fob
5 Mar 24
Shuttle Pharmaceuticals to Present at About Shuttle Pharmaceuticals
9:00am
8-K
kvn9gwew g1
13 Feb 24
Shuttle Pharma Announces Its Intent to Pursue a Rights Offering
8:00am
8-K
ohcm8hwe
5 Feb 24
Entry into a Material Definitive Agreement
4:25pm
8-K
yvhg7t319o o5i
8 Jan 24
Shuttle Pharmaceuticals Receives FDA approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
9:05am
8-K
n6ta0vpd42z 3xldc8b
19 Dec 23
Submission of Matters to a Vote of Security Holders
5:10pm
8-K
rsuwl w1y65v
11 Dec 23
Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma
9:00am
8-K
cis4o8d9z4w 84p
30 Nov 23
Other Events
9:00am
8-K
rwj rfyp1qtduz95
14 Nov 23
Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update
12:00am
8-K
1ve7leud
30 Oct 23
Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement
5:14pm
ARS
gti2j9oj
20 Oct 23
Annual report to shareholders
4:15pm